Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's Disease.


Journal

Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170

Informations de publication

Date de publication:
03 03 2020
Historique:
received: 25 07 2019
revised: 25 10 2019
accepted: 07 02 2020
entrez: 5 3 2020
pubmed: 5 3 2020
medline: 2 7 2021
Statut: ppublish

Résumé

Alteration of brain aerobic glycolysis is often observed early in the course of Alzheimer's disease (AD). Whether and how such metabolic dysregulation contributes to both synaptic plasticity and behavioral deficits in AD is not known. Here, we show that the astrocytic l-serine biosynthesis pathway, which branches from glycolysis, is impaired in young AD mice and in AD patients. l-serine is the precursor of d-serine, a co-agonist of synaptic NMDA receptors (NMDARs) required for synaptic plasticity. Accordingly, AD mice display a lower occupancy of the NMDAR co-agonist site as well as synaptic and behavioral deficits. Similar deficits are observed following inactivation of the l-serine synthetic pathway in hippocampal astrocytes, supporting the key role of astrocytic l-serine. Supplementation with l-serine in the diet prevents both synaptic and behavioral deficits in AD mice. Our findings reveal that astrocytic glycolysis controls cognitive functions and suggest oral l-serine as a ready-to-use therapy for AD.

Identifiants

pubmed: 32130882
pii: S1550-4131(20)30063-2
doi: 10.1016/j.cmet.2020.02.004
pii:
doi:

Substances chimiques

Receptors, N-Methyl-D-Aspartate 0
Serine 452VLY9402
Phosphoglycerate Dehydrogenase EC 1.1.1.95
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

503-517.e8

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Juliette Le Douce (J)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Marianne Maugard (M)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Julien Veran (J)

Neurocentre Magendie, INSERM U1215, Bordeaux, France; Université de Bordeaux, Bordeaux, France.

Marco Matos (M)

Neurocentre Magendie, INSERM U1215, Bordeaux, France; Université de Bordeaux, Bordeaux, France.

Pierrick Jégo (P)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Pierre-Antoine Vigneron (PA)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Emilie Faivre (E)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Xavier Toussay (X)

Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), Paris, France.

Michel Vandenberghe (M)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Yaël Balbastre (Y)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Juliette Piquet (J)

Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), Paris, France.

Elvire Guiot (E)

Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), Paris, France.

Nguyet Thuy Tran (NT)

Université Paris-Saclay, CNRS, Institut Galien Paris Sud, Châtenay-Malabry, France.

Myriam Taverna (M)

Université Paris-Saclay, CNRS, Institut Galien Paris Sud, Châtenay-Malabry, France; Institut Universitaire de France (IUF), Paris, France.

Stéphane Marinesco (S)

AniRA-NeuroChem Technological Platform, Lyon Neuroscience Research Center, CNRS, UMR 5292, INSERM U1028, University Claude Bernard Lyon 1, Lyon, France.

Ayumi Koyanagi (A)

Laboratory of Functional Genomics and Metabolism, Department of Bioscience and Biotechnology, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Shigeki Furuya (S)

Laboratory of Functional Genomics and Metabolism, Department of Bioscience and Biotechnology, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Mylène Gaudin-Guérif (M)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Sébastien Goutal (S)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Aurélie Ghettas (A)

Université Paris-Saclay, CEA, INRAE, Département Médicaments et technologies pour la santé, Gif-sur-Yvette, France.

Alain Pruvost (A)

Université Paris-Saclay, CEA, INRAE, Département Médicaments et technologies pour la santé, Gif-sur-Yvette, France.

Alexis-Pierre Bemelmans (AP)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Marie-Claude Gaillard (MC)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Karine Cambon (K)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Lev Stimmer (L)

INSERM US27, Platform for Experimental Pathology, MIRCen, Fontenay-aux-Roses, France.

Véronique Sazdovitch (V)

Laboratoire de Neuropathologie Raymond Escourolle, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.

Charles Duyckaerts (C)

Laboratoire de Neuropathologie Raymond Escourolle, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.

Graham Knott (G)

BioEM Facility, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

Anne-Sophie Hérard (AS)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Thierry Delzescaux (T)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Philippe Hantraye (P)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Emmanuel Brouillet (E)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France.

Bruno Cauli (B)

Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS), Paris, France.

Stéphane H R Oliet (SHR)

Neurocentre Magendie, INSERM U1215, Bordeaux, France; Université de Bordeaux, Bordeaux, France.

Aude Panatier (A)

Neurocentre Magendie, INSERM U1215, Bordeaux, France; Université de Bordeaux, Bordeaux, France. Electronic address: aude.panatier@inserm.fr.

Gilles Bonvento (G)

Université Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses, France. Electronic address: gilles.bonvento@cea.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH